Safety Profile

PT-141 Side Effects & Safety

PT-141 (bremelanotide) is FDA approved for HSDD with a well-characterized side effect profile from Phase III trials.

Educational content only. This page is compiled from published research for reference and is not medical advice, diagnosis, or treatment. Readers should verify claims against primary sources and consult a qualified healthcare provider before making any health decisions. Full disclaimer.

Side effects by severity

Common4 effects

Nausea

40%

Most common side effect; typically mild to moderate.

Flushing

20%

Facial flushing related to melanocortin activation.

Headache

11%

Usually mild.

Transient BP increase

Small increase for ~12 hours after dose. Do not use in uncontrolled hypertension or CV disease.

Uncommon3 effects

Vomiting

More common at higher doses.

Injection site reactions

Mild pain or erythema.

Skin hyperpigmentation

Focal or generalized darkening in ~1% with repeated use.

Rare1 effect

Priapism (males, off-label)

Theoretical risk in male off-label use.

Contraindications

Uncontrolled hypertension
Known cardiovascular disease
Known hypersensitivity

Drug interactions

Naltrexone (oral) — reduced naltrexone effectiveness
Antihypertensives — PT-141 may counteract antihypertensive effect

Special populations

Not recommended in pregnancy or lactation. Limited elderly data.

Safety summary

PT-141 has a favorable risk-benefit profile for HSDD. The transient blood pressure increase is the most clinically relevant consideration and contraindicates use in uncontrolled hypertension.

Frequently asked

Can PT-141 cause permanent skin darkening?

Focal hyperpigmentation occurs in ~1% of users with repeated dosing. It may persist after discontinuation but typically fades.